; Whereas the underrepresentation of people of color, from both urban and rural communities, in clinical trials perpetuates and exacerbates racial and ethnic cancer inequities and disparities, and limits access to potentially lifesaving treatments; Whereas, in 2021, the Director of the Centers for Disease Control and Prevention declared racism a serious public health threat and announced efforts undertaken by the agency to accelerate its efforts to address racism as a fundamental driver of racial and ethnic health disparities and inequities; Whereas research suggests that racial and ethnic disparities in cancer and in cancer care are driven by systemic inequities both in society and within and throughout the United States health system that are rooted in racism and discrimination; Whereas significant racial and ethnic disparities exist in access to treatment according to nationally recognized cancer care guidelines; Whereas these disparities have a profound impact on stage of cancer diagnoses, access to consistent and quality cancer care, optimal patient outcomes, quality of life, and overall health equity; Whereas addressing and closing the cancer care gap is an urgent priority, and in recognition of this, the American Cancer Society Cancer Action Network, the National Minority Quality Forum, and the National Comprehensive Cancer Network formed the Alliance for Cancer Care Equity (ACCE); Whereas ACCE is a group of health equity and patient advocates, community-based organizations, and professional societies working to support policies, promote practices, and create systems that prioritize the elimination of racial and ethnic disparities and inequities across all cancers; and Whereas, in 2024, commemorations for World Cancer Day recognize the vital role of governments in advancing cancer care by eliminating racial and ethnic disparities and inequities in access to prevention, early screening and diagnostic services, and quality care and treatment: Now, therefore, be it